Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Debt Repayments (2021 - 2022)

Tg Therapeutics has reported Long-Term Debt Repayments over the past 2 years, most recently at -$975000.0 for Q1 2022.

  • Quarterly results put Long-Term Debt Repayments at -$975000.0 for Q1 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was -$975000.0 (changed N/A YoY), and the annual figure for FY2024 was -$107.6 million, changed.
  • Long-Term Debt Repayments for Q1 2022 was -$975000.0 at Tg Therapeutics, up from -$15.4 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for TGTX hit a ceiling of -$975000.0 in Q1 2022 and a floor of -$15.4 million in Q4 2021.